An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors.
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharma
- 19 May 2016 Results published in the Targeted Oncology
- 17 Nov 2012 Planned number of patients changed from 200 to 400 as reported by EudraCT (Parent trial: EudraCT2010-023032-17).
- 07 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History